Bayer recently announced that it would be laying off a further 70 employees at its US headquarters in Whippany, New Jersey where 90 employees were laid off four months ago.
The layoffs are part of Bayer’s new restructuring plan aimed at cutting bureaucracy and bringing dividends down to the legal minimum level in the next three years.
Back in June this year, the company’s pharmaceutical department revealed to Reuters that it would also continue to cut managerial roles in Japan, Germany, the Netherlands, Belgium and the UK. The department has already downsized significantly in the US, Mexico, Canada, Italy, the Nordic countries and Australia.
As reported by Fierce Pharma, Bayer said in an email statement, “We are adopting a new operating model and with it, a new organisational structure. Our new way of working will enable more agility, empower employees to innovate and act, and deepen the focus on our mission.
“Aligned with this shift, we are adjusting our US structure, resulting in some positions being eliminated or redesigned, and a few new roles being created.”
https://www.euronews.com/business/2024/08/06/bayer-reaps-benefits-of-strong-demand-for-new-cancer-and-kidney-dr-gs